Sensus Healthcare (NASDAQ:SRTS) and Hypertension Diagnostics (OTCMKTS:HDII) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, institutional ownership, earnings and dividends.

Volatility and Risk

Sensus Healthcare has a beta of -0.58, suggesting that its stock price is 158% less volatile than the S&P 500. Comparatively, Hypertension Diagnostics has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.

Profitability

This table compares Sensus Healthcare and Hypertension Diagnostics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sensus Healthcare -10.21% -16.98% -11.03%
Hypertension Diagnostics N/A N/A N/A

Institutional and Insider Ownership

13.2% of Sensus Healthcare shares are held by institutional investors. Comparatively, 0.0% of Hypertension Diagnostics shares are held by institutional investors. 41.1% of Sensus Healthcare shares are held by insiders. Comparatively, 40.0% of Hypertension Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Sensus Healthcare and Hypertension Diagnostics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sensus Healthcare $20.59 million 6.24 -$3.71 million ($0.28) -28.54
Hypertension Diagnostics N/A N/A N/A N/A N/A

Hypertension Diagnostics has lower revenue, but higher earnings than Sensus Healthcare.

Analyst Recommendations

This is a summary of current ratings and target prices for Sensus Healthcare and Hypertension Diagnostics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sensus Healthcare 0 1 5 0 2.83
Hypertension Diagnostics 0 0 0 0 N/A

Sensus Healthcare presently has a consensus price target of $11.80, suggesting a potential upside of 47.68%. Given Sensus Healthcare’s higher probable upside, equities research analysts plainly believe Sensus Healthcare is more favorable than Hypertension Diagnostics.

Summary

Sensus Healthcare beats Hypertension Diagnostics on 5 of the 9 factors compared between the two stocks.

About Sensus Healthcare

Sensus Healthcare, Inc. manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides Sentinel service program, which offers its customers protection for their SRT-100 and SRT-100 Vision systems. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons, eye shields, and disposable applicator tips, which are used to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was founded in 2010 and is headquartered in Boca Raton, Florida.

About Hypertension Diagnostics

Hypertension Diagnostics, Inc. designs, develops, manufactures, and markets proprietary noninvasive medical devices that detect subtle changes in the elasticity of arteries in the United States and internationally. It offers CVProfilor, which allows a physician to non-invasively assess the elasticity of small and large arteries, of which small artery elasticity is the earliest and sensitive marker of cardiovascular disease. The company offers CVProfilor DO-2020, which provides a patient's arterial elasticity indices used in the assessment for underlying vascular disease; CVProfilor MD-3000 that offers a sensitive and specific guide to the presence of blood vessel disease; and HD/PulseWave CR-2000 research cardiovascular profiling system, which provides researchers and scientists with a non-invasive means to assess arterial elasticity in support of human research in various areas. Its products collect 30 seconds of blood pressure waveform data, perform an analysis of the digitized blood pressure waveforms, and generate a CVProfile report that contains information on blood pressure, heart rate, pulse pressure, body surface area, body mass index, and C1-large and C2-small artery elasticity indices. The company sells its products to primary care physicians, cardiologists, health care professionals, trained medical personnel, research investigators at academic medical research centers, government institutes, cardiovascular specialists, and pharmaceutical firms. It markets its products through a representative organization in the United States. Hypertension Diagnostics, Inc. was founded in 1988 and is based in Minnetonka, Minnesota.

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.